ストックスクリーナーアプリを入手
5.1182
4.15%
-0.2218
前日終値:
$5.34
開ける：
$5.31
24時間の取引高:
283.96K
Relative Volume:
0.27
時価総額：
$223.68M
収益：
$124.00K
当期純損益:
$-49.99M
株価収益率:
-3.0285
EPS:
-1.69
ネットキャッシュフロー:
$-31.03M
1週間 パフォーマンス:
+7.53%
1か月 パフォーマンス:
+3.40%
6か月 パフォーマンス:
+34.69%
1年 パフォーマンス:
-63.44%
1日の値動き範囲:
$5.03
$5.365
1週間の範囲:
$4.63
$5.59
52週間の値動き範囲:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
CADL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.12 | 223.68M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.64 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.69 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
543.08 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.61 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-20 | 開始されました | Citigroup | Buy |
| 2025-02-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-07 | 開始されました | BofA Securities | Buy |
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-08-23 | 開始されました | Credit Suisse | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
| 2021-08-23 | 開始されました | UBS | Buy |
すべてを表示
Candel Therapeutics Inc (CADL) 最新ニュース
Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics - TipRanks
Candel Therapeutics Reports Strong Q1 2025 Results - TipRanks
CADL's Cash Reserves Projected to Last Until Early 2027 | CADL S - GuruFocus
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - MSN
CADL To Present Prostate Cancer Trial Data, RMD's Q3 Revenue Climbs 8%, AUNA On Watch... - RTTNews
Small cap wrap: Candel Therapeutics, Nevis Brands, Fineqia, Voyageur Pharmaceuticals, atai... - Proactive Investors
Candel Therapeutics (CADL) Reports Q1 Earnings and Cash Reserves - GuruFocus
Market movers: Coinbase, Hertz, Candel Therapeutics, JD Sports... - Proactive Investors
Cardell Flat on Q1 - Baystreet.ca
Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drug - Proactive financial news
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Candel Therapeutics to present at upcoming healthcare conferences - Proactive financial news
Candel Therapeutics to Present at Upcoming Investor Conferences in May and June 2025 - Nasdaq
Candel Therapeutics Inc [CADL] stock for 396,995 USD was sold by Nichols William Garrett - knoxdaily.com
Is Candel Therapeutics Inc (CADL) worth investing in despite its overvalued state? - uspostnews.com
LPL Financial LLC Makes New Investment in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Financial Metrics Check: Candel Therapeutics Inc (CADL)’s Ratios for Trailing Twelve Months - DWinneX
Geode Capital Management LLC Grows Stock Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
S3e01 Life Changing Innovation with Paul Peter Tak, CEO of Candel Therapeutics - iHeart
A new trading data show Candel Therapeutics Inc (CADL) is showing positive returns. - Sete News
Candel Therapeutics to Present Prostate Cancer Trial Data By Investing.com - Investing.com India
Candel Therapeutics to Present Prostate Cancer Trial Data - Investing.com
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - The Manila Times
Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting - Nasdaq
Candel Therapeutics Announces Oral Presentation of Positive - GlobeNewswire
Major Phase 3 Trial Results: Breakthrough Prostate Cancer Treatment Data to be Revealed at ASCO 2025 - Stock Titan
Candel Therapeutics to present Phase 3 prostate cancer data at 2025 ASCO Annual Meeting - Proactive Investors
Technical analysis of Candel Therapeutics Inc (CADL) stock chart patterns - uspostnews.com
How To Trade (CADL) - news.stocktradersdaily.com
Candel Therapeutics (NASDAQ:CADL) Earns “Buy” Rating from HC Wainwright - Defense World
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire
Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewswire
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI | NASDAQ:CADL - Proactive Investors
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - AOL.com
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com
Candel Therapeutics Reports Both Prolonged Median Overall - GlobeNewswire
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
Candel Therapeutics Inc (CADL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Mar 18 '25 |
Sale |
8.76 |
45,316 |
396,995 |
52,493 |
| Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Option Exercise |
1.55 |
18,000 |
27,900 |
128,673 |
| Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Sale |
8.76 |
32,146 |
281,673 |
96,527 |
| Tak Paul Peter | Chief Executive Officer |
Mar 18 '25 |
Sale |
8.77 |
25,772 |
226,023 |
226,140 |
| Tak Paul Peter | Chief Executive Officer |
Mar 19 '25 |
Sale |
9.00 |
400 |
3,601 |
225,740 |
| Tyagarajan Seshu | Chief Technology Officer |
Mar 17 '25 |
Sale |
8.82 |
31,278 |
275,947 |
85,512 |
| Schoch Charles | See Remarks |
Mar 17 '25 |
Sale |
8.83 |
5,000 |
44,169 |
38,038 |
0.57%
1.03%
大文字化:
|
ボリューム (24 時間):